# OnCo record obsidian-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/obsidian-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "obsidian-therapeutics" ;
  schema:name "Obsidian Therapeutics"@en ;
  schema:description "Obsidian grows a patient's own tumour-fighting immune cells and engineers them with a switch that lets doctors control a growth signal (IL-15) with an oral drug, aiming to make TIL therapy safer and more effective for melanoma and lung cancer. It listed on Nasdaq in August 2026 after raising $350 million."@en ;
  schema:url <https://onco.cc/companies/obsidian-therapeutics/>, <https://obsidiantx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://obsidiantx.com/>, <https://www.sec.gov/Archives/edgar/data/1563577/000119312526154009/d124753dex991.htm>, <https://www.sec.gov/Archives/edgar/data/2130606/000119312526330810/d309963dex991.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/til-therapy/> ;
  onco:trials <https://onco.cc/trials/nct06060613/> .